Resource Archives:University Hospital's HealthLink On Air

Meet Our Guests
September 7, 2008

Photo of This Week's Guest
Shelley Gilroy, MD

Topic: LYME DISEASE

Photo of This Week's Guest
David Duggan, MD

Topic: MEDICARE & MEDICAID

University Hospital
& SUNY Upstate
Medical University

ABOUT the HOST—

Trisha Torrey...

Every Patient's Advocate

Important Information
for Website Visitors &
Program Listeners

Call Us at: 315 464-4545
Toll Free: 877 464-4545

Coming up on September 23rd's Show:

Atrial fibrillation is the rapid, uncoordinated twitching of the heart muscle that supplants its normal rhythmic contraction and can result in poor circulation, weak pulse and even death. Dr. Robert Carhart, chief of cardiology at University Hospital and professor of medicine at SUNY Upstate Medical University discusses its causes and treatments. Infection control specialist Dr. Shelley Gilroy starts the flu season off with the pros and the few cons to getting an annual flu shot, and discusses how it's determined which flu will run rampant one year before it actually hits.

On September 16th's Show:

Scott Murray, PharmD, talks about the new fat-burning drug Alli and the pros and cons of diet drugs and the side effects pharmaceutical companies don't like to talk about.

Read more about: Pharmacy Services at University Hospital.

Health Information Center Resources for Antiobesity Drugs:

Easy to Read Drug Information:

Orlistat, content update for Chapter 27, Overweight and Obesity, Handbook of Nonprescription Drugs.
Meridia, from PDRhealth.
Xenical, from PDRhealth.
Orlistat, Alli and Xenical, from MedlinePlus.

Professional Journals:

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. PA Hollander et al. Diabetes Care. Vol 21: 1288-1294.

Effect of Orlistat on Weight Regain and Cardiovascular Risk Factors Following a Very-Low-Energy Diet in Abdominally Obese Patients. A 3-year randomized, placebo-controlled study. Bjon Richelsen. Diabetes Care Vol. 30: 27-32.

Role of Orlistat in the Treatment of Obese Patients With Type 2 Diabetes. A 1-year randomized double-blind study. P. A. Hollander et al Diabetes Care. Vol 21: 1288-1294.

Medical News:

Orlistat Plus Lifestyle Intervention May Be Safe, Effective for Overweight Adolescents, from Medscape Today (may require a short registration).

Orlistat Plus Lifestyle Changes Can Reduce the Incidence of Type 2 Diabetes, from Medscape Today (may require a short registration).

Low-Dose Orlistat Provides Significant Weight Loss And Multiple Health Benefits, from Medical News Today.

FDA Approves Alli (orlistat 60 Mg Capsules) Over-the-counter, from Medical News Today.

News and Views...

A Heart Drug May Hold Off Alzheimer's